{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:05:13Z","timestamp":1794027913549,"version":"4.8.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T00:00:00Z","timestamp":1592265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T00:00:00Z","timestamp":1592265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Phelan-McDermid Syndrome (PMS) is a rare neurodevelopmental disorder characterized by global developmental delay, autism spectrum disorder, and numerous systemic complications including seizures, gastrointestinal dysfunction, and renal anomalies. The Phelan-McDermid Syndrome Foundation (PMSF) was created to improve the quality of life of people affected by PMS worldwide by supporting families, accelerating research, and raising awareness. To further this mission, the PMSF initiated the Phelan-McPosium in 2016 to bring families affected by PMS, clinicians, and researchers together to design patient-centered rigorous clinical and translational research. Here, we present findings from the 2018 Phelan-McPosium.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>The 2018 Phelan-McPosium was attended by 183 families and 35 researchers and clinicians. Overall, the Early Childhood parents raised the fewest number of concerns, families of Late-Childhood patients raised more concerns around epilepsy and behavioral problems, and Teen and Adult families were primarily concerned about implications of genetic testing, gastrointestinal dysfunction, and regression. All families were concerned with feasibility, safety and importance of clinical trials for PMS.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The concerns raised by families across the sessions varied by age in a manner which may overlap with the emergence of various signs and symptoms through the natural history of PMS. The design of the Phelan-McPosium session has successfully generated thoughtful research questions that led to innovative investigations and clinical trials that are shaping the standard of care for PMS. This is an approach which could be employed by any rare disease group to align translational research efforts with a patient-centered focus.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13023-020-01389-6","type":"journal-article","created":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T12:02:36Z","timestamp":1592308956000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Bringing everyone to the table \u2013 findings from the 2018 Phelan-McDermid Syndrome Foundation International Conference"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8823-2839","authenticated-orcid":false,"given":"Kimberly","family":"Goodspeed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine","family":"Bliss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Linnehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,16]]},"reference":[{"issue":"7","key":"1389_CR1","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00439-014-1423-7","volume":"133","author":"SM Sarasua","year":"2014","unstructured":"Sarasua SM, Boccuto L, Sharp JL, Dwivedi A, Chen CF, Rollins JD, et al. Clinical and genomic evaluation of 201 patients with Phelan-McDermid syndrome. Hum Genet. 2014;133(7):847\u201359.","journal-title":"Hum Genet"},{"issue":"1","key":"1389_CR2","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/2040-2392-4-18","volume":"4","author":"L Soorya","year":"2013","unstructured":"Soorya L, Kolevzon A, Zweifach J, Lim T, Dobry Y, Schwartz L, et al. Prospective investigation of autism and genotype-phenotype correlations in 22q13 deletion syndrome and SHANK3 deficiency. Mol Autism. 2013;4(1):18.","journal-title":"Mol Autism."},{"issue":"1","key":"1389_CR3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1866-1955-6-39","volume":"6","author":"A Kolevzon","year":"2014","unstructured":"Kolevzon A, Angarita B, Bush L, Wang AT, Frank Y, Yang A, et al. Phelan-McDermid syndrome: a review of the literature and practice parameters for medical assessment and monitoring. J Neurodev Disord. 2014;6(1):39.","journal-title":"J Neurodev Disord"},{"issue":"8","key":"1389_CR4","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1136\/jmg.40.8.575","volume":"40","author":"HL Wilson","year":"2003","unstructured":"Wilson HL, Wong AC, Shaw SR, Tse WY, Stapleton GA, Phelan MC, et al. Molecular characterisation of the 22q13 deletion syndrome supports the role of haploinsufficiency of SHANK3\/PROSAP2 in the major neurological symptoms. J Med Genet. 2003;40(8):575\u201384.","journal-title":"J Med Genet"},{"key":"1389_CR5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1750-1172-3-14","volume":"3","author":"MC Phelan","year":"2008","unstructured":"Phelan MC. Deletion 22q13.3 syndrome. Orphanet J Rare Dis. 2008;3:14.","journal-title":"Orphanet J Rare Dis"},{"issue":"14","key":"1389_CR6","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1177\/0883073815600872","volume":"30","author":"H Harony-Nicolas","year":"2015","unstructured":"Harony-Nicolas H, De Rubeis S, Kolevzon A, Buxbaum JD. Phelan McDermid syndrome: from genetic discoveries to animal models and treatment. J Child Neurol. 2015;30(14):1861\u201370.","journal-title":"J Child Neurol"},{"key":"1389_CR7","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.neubiorev.2016.01.001","volume":"63","author":"J Costales","year":"2016","unstructured":"Costales J, Kolevzon A. The therapeutic potential of insulin-like growth factor-1 in central nervous system disorders. Neurosci Biobehav Rev. 2016;63:207\u201322.","journal-title":"Neurosci Biobehav Rev"},{"issue":"1","key":"1389_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/2040-2392-4-9","volume":"4","author":"O Bozdagi","year":"2013","unstructured":"Bozdagi O, Tavassoli T, Buxbaum JD. Insulin-like growth factor-1 rescues synaptic and motor deficits in a mouse model of autism and developmental delay. Mol Autism. 2013;4(1):9.","journal-title":"Mol Autism."},{"issue":"1","key":"1389_CR9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/2040-2392-5-54","volume":"5","author":"A Kolevzon","year":"2014","unstructured":"Kolevzon A, Bush L, Wang AT, Halpern D, Frank Y, Grodberg D, et al. A pilot controlled trial of insulin-like growth factor-1 in children with Phelan-McDermid syndrome. Mol Autism. 2014;5(1):54.","journal-title":"Mol Autism."},{"issue":"10","key":"1389_CR10","doi-asserted-by":"publisher","first-page":"S258","DOI":"10.1016\/j.jaac.2017.09.299","volume":"56","author":"MF Snape","year":"2017","unstructured":"Snape MF, Horrigan JP, Deacon RMJ, Hurley MJ, Cogram P. 5.16 AMO-01 in the SHANK3 knockout transgenic mouse model of Phelan Mcdermid syndrome. J Am Acad Child Adolesc Psychiatry. 2017;56(10):S258\u2013S9.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"10","key":"1389_CR11","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1111\/epi.13506","volume":"57","author":"JL Holder Jr","year":"2016","unstructured":"Holder JL Jr, Quach MM. The spectrum of epilepsy and electroencephalographic abnormalities due to SHANK3 loss-of-function mutations. Epilepsia. 2016;57(10):1651\u20139.","journal-title":"Epilepsia."},{"issue":"4","key":"1389_CR12","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/gim.2013.144","volume":"16","author":"SM Sarasua","year":"2014","unstructured":"Sarasua SM, Dwivedi A, Boccuto L, Chen CF, Sharp JL, Rollins JD, et al. 22q13.2q13.32 genomic regions associated with severity of speech delay, developmental delay, and physical features in Phelan-McDermid syndrome. Genet Med. 2014;16(4):318\u201328.","journal-title":"Genet Med"},{"issue":"9","key":"1389_CR13","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.seizure.2014.06.008","volume":"23","author":"MG Figura","year":"2014","unstructured":"Figura MG, Coppola A, Bottitta M, Calabrese G, Grillo L, Luciano D, et al. Seizures and EEG pattern in the 22q13.3 deletion syndrome: clinical report of six Italian cases. Seizure. 2014;23(9):774\u20139.","journal-title":"Seizure."},{"key":"1389_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13229-018-0205-9","volume":"9","author":"S De Rubeis","year":"2018","unstructured":"De Rubeis S, Siper PM, Durkin A, Weissman J, Muratet F, Halpern D, et al. Delineation of the genetic and clinical spectrum of Phelan-McDermid syndrome caused by SHANK3 point mutations. Mol Autism. 2018;9:31.","journal-title":"Mol Autism"},{"issue":"Pt. 6","key":"1389_CR15","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1365-2788.2006.00877.x","volume":"51","author":"DG Allen","year":"2007","unstructured":"Allen DG, Lowe K, Moore K, Brophy S. Predictors, costs and characteristics of out of area placement for people with intellectual disability and challenging behaviour. J Intellect Disabil Res. 2007;51(Pt. 6):409\u201316.","journal-title":"J Intellect Disabil Res"},{"issue":"Pt 5","key":"1389_CR16","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/j.1365-2788.1995.tb00543.x","volume":"39","author":"E Emerson","year":"1995","unstructured":"Emerson E, Bromley J. The form and function of challenging behaviours. J Intellect Disabil Res. 1995;39(Pt 5):388\u201398.","journal-title":"J Intellect Disabil Res"},{"key":"1389_CR17","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/1044207311420567","volume":"23","author":"AG Hall","year":"2012","unstructured":"Hall AG, Bouldin ED, Andresen EM, Ali AK. Maintaining employment among caregivers of individuals on a medic aid waitlist for services. J Disabil Policy Stud. 2012;23:121\u20138.","journal-title":"J Disabil Policy Stud"},{"issue":"2","key":"1389_CR18","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.rasd.2012.09.006","volume":"7","author":"DME Sikora","year":"2013","unstructured":"Sikora DME, Orlich F, Hall TA, Kovacs EA, Delahave J, Kuhlthau K. The relationship between family functioning and behavior problem in children with autism spectrum disorders. Res Autism Spectr Disord. 2013;7(2):307\u201315.","journal-title":"Res Autism Spectr Disord"},{"issue":"2","key":"1389_CR19","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1080\/13668250902874608","volume":"34","author":"K Davis","year":"2009","unstructured":"Davis K, Gavidia-Payne S. The impact of child, family, and professional support characteristics on the quality of life in families of young children with disabilities. J Intellect Develop Disabil. 2009;34(2):153\u201362.","journal-title":"J Intellect Develop Disabil"},{"issue":"5","key":"1389_CR20","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1037\/a0029354","volume":"26","author":"SL Hartley","year":"2012","unstructured":"Hartley SL, Barker ET, Baker JK, Seltzer MM, Greenberg JS. Marital satisfaction and life circumstances of grown children with autism across 7 years. J Fam Psychol. 2012;26(5):688\u201397.","journal-title":"J Fam Psychol"},{"issue":"1","key":"1389_CR21","first-page":"3","volume":"2","author":"BA Iwata","year":"1982","unstructured":"Iwata BA, Dorsey MF, Slifer KJ, Bauman KE, Richman GS. Toward a functional analysis of self-injury. Anal Interv Dev Disabil. 1982;2(1):3\u201320.","journal-title":"Anal Interv Dev Disabil"},{"issue":"7","key":"1389_CR22","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1007\/s10803-015-2375-z","volume":"45","author":"NA Call","year":"2015","unstructured":"Call NA, Simmons CA, Mevers JE, Alvarez JP. Clinical outcomes of behavioral treatments for Pica in children with developmental disabilities. J Autism Dev Disord. 2015;45(7):2105\u201314.","journal-title":"J Autism Dev Disord"},{"issue":"2","key":"1389_CR23","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/jaba.379","volume":"50","author":"NA Call","year":"2017","unstructured":"Call NA, Mevers JL, McElhanon BO, Scheithauer MC. A multidisciplinary treatment for encopresis in children with developmental disabilities. J Appl Behav Anal. 2017;50(2):332\u201344.","journal-title":"J Appl Behav Anal"},{"key":"1389_CR24","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jpeds.2017.11.028","volume":"195","author":"KC Williams","year":"2018","unstructured":"Williams KC, Rogers LK, Hill I, Barnard J, Di Lorenzo C. PEG 3350 administration is not associated with sustained elevation of glycol levels. J Pediatr. 2018;195:148\u201353 e1.","journal-title":"J Pediatr"},{"key":"1389_CR25","unstructured":"(GARD) GaRDIC. Developmental Regression. Available from: https:\/\/rarediseases.info.nih.gov\/glossary\/letter-d. Cited 2019."},{"issue":"3","key":"1389_CR26","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/ajmg.a.33253","volume":"152A","author":"SU Dhar","year":"2010","unstructured":"Dhar SU, del Gaudio D, German JR, Peters SU, Ou Z, Bader PI, et al. 22q13.3 deletion syndrome: clinical and molecular analysis using array CGH. Am J Med Genet A. 2010;152A(3):573\u201381.","journal-title":"Am J Med Genet A"},{"issue":"7","key":"1389_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1002173","volume":"7","author":"MC Bonaglia","year":"2011","unstructured":"Bonaglia MC, Giorda R, Beri S, De Agostini C, Novara F, Fichera M, et al. Molecular mechanisms generating and stabilizing terminal 22q13 deletions in 44 subjects with Phelan\/McDermid syndrome. PLoS Genet. 2011;7(7):e1002173.","journal-title":"PLoS Genet"},{"issue":"2","key":"1389_CR28","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.gene.2013.03.141","volume":"524","author":"M Macedoni-Luksic","year":"2013","unstructured":"Macedoni-Luksic M, Krgovic D, Zagradisnik B, Kokalj-Vokac N. Deletion of the last exon of SHANK3 gene produces the full Phelan-McDermid phenotype: a case report. Gene. 2013;524(2):386\u20139.","journal-title":"Gene."},{"key":"1389_CR29","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13229-015-0020-5","volume":"6","author":"DM Cochoy","year":"2015","unstructured":"Cochoy DM, Kolevzon A, Kajiwara Y, Schoen M, Pascual-Lucas M, Lurie S, et al. Phenotypic and functional analysis of SHANK3 stop mutations identified in individuals with ASD and\/or ID. Mol Autism. 2015;6:23.","journal-title":"Mol Autism."},{"key":"1389_CR30","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12888-015-0490-1","volume":"15","author":"S Serret","year":"2015","unstructured":"Serret S, Thummler S, Dor E, Vesperini S, Santos A, Askenazy F. Lithium as a rescue therapy for regression and catatonia features in two SHANK3 patients with autism spectrum disorder: case reports. BMC Psychiatry. 2015;15:107.","journal-title":"BMC Psychiatry"},{"key":"1389_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13229-018-0250-4","volume":"10","author":"DM James","year":"2019","unstructured":"James DM, Kozol RA, Kajiwara Y, Wahl AL, Storrs EC, Buxbaum JD, et al. Intestinal dysmotility in a zebrafish (Danio rerio) shank3a;shank3b mutant model of autism. Mol Autism. 2019;10:3.","journal-title":"Mol Autism."},{"key":"1389_CR32","unstructured":"Rare Facts. Available from: https:\/\/globalgenes.org\/rare-facts\/. Accessed 2 Apr 2019."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01389-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-020-01389-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01389-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T23:21:05Z","timestamp":1623799265000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-020-01389-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,16]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1389"],"URL":"https:\/\/doi.org\/10.1186\/s13023-020-01389-6","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,16]]},"assertion":[{"value":"12 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study received exempt status from the UT Southwestern Institutional Review Board.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Ms. Bliss reports personal fees from ASDDR, outside the submitted work.Ms. Linnehan reports other from Phelan-McDermid Syndrome Foundation, outside the submitted work .","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"152"}}